Citation

Is EA Biosecurity Work Limited to Restricting LLM Biological Use? - Footnote 19

partial90% confidence

1 evidence check

Last checked: 4/3/2026

The source does not specify the year the seed round was raised. The claim states it was in 2025, which is not verifiable from the source. The source states that Red Queen Bio spun out of HelixNano, not HelixNano (clinical-stage mRNA therapeutics).

Evidence — 1 source, 1 check

www.redqueen.bio/(1 check)

partial90%Haiku 4.5 · 4/3/2026

Found: - **<EntityLink id="red-queen-bio">Red Queen Bio</EntityLink>** — Spun out of HelixNano (clinical-stage mRNA therapeutics), raised a **\$15M seed round led by OpenAI** in 2025. Core thesis: "defensive…

Note: The source does not specify the year the seed round was raised. The claim states it was in 2025, which is not verifiable from the source. The source states that Red Queen Bio spun out of HelixNano, not HelixNano (clinical-stage mRNA therapeutics).

Debug info

Record type: citation

Record ID: page:ea-biosecurity-scope:fn19